Transparency data

Non-tech. summaries 2014: projects on oncology

Projects granted during 2014 that have a primary purpose of basic research: oncology.


Non-technical summaries: projects granted in 2014, volume 14

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email Please tell us what format you need. It will help us if you say what assistive technology you use.


This document outlines the projects granted under the Animals (Scientific Procedures) Act 1986 during 2014 with a primary purpose of basic research: oncology.

The following projects were granted:

  • identification and validation of novel therapeutic targets for human cancer (oncogenes, tumour suppressor genes, immune system, small molecule inhibitor, catechins)

  • significance of alternative slicing in vivo (tumours, metastasis, splice factors)

  • controlling CD8+ T cell-mediated immune responses to tumours (cancer tumour immunity)

  • pathogenesis of avian oncogenic viruses (Marek’s disease, avian leukosis, lymphomas, reticuloendotheliosis, multiple infections)

  • studies on cancer cachexia and obesity/type II diabetes (cachexia, tumour factors, weight loss, diabetes)

  • studies on urological cancer (prostate cancer, bladder cancer, kidney cancer)

  • brain metastasis: imaging and inflammation (brain, tumour, imaging, inflammation, metabolism)

  • role of inflammation in pancreatic cancer (cancer, inflammation, tumour micro environment, pancreas)

  • generation and characterisation of human derived tumour xenografts or PDXs (breast cancer in vivo expansion engraftment)

  • FAP+ stromal cell response to biological stress (cancer, lymphocytes, cachexia, metabolism, development)

  • metabolic dysfunction in cancer progression (mitochondria, autophagy, CAFs, oxidative phosphorylation, caveolin)

  • ribosomal and metabolic stress responses in cancer (ribosome, metabolism, cancer, therapy, stress)

  • signalling pathways in physiology and oncogenesis (genes, cells, signalling, development, cancer)

  • targeted mouse models for pre-clinical studies (genetically engineered mouse models, cancer, targeted therapeutics, pre-clinical)

  • targeted therapy for cancer (cancer, gene therapy, radiation, radiosensitiser, virus therapy)

  • temporal analysis of cancer evolution in vivo (cancer, biomarker, therapy)

  • manipulating cellular and microenvironment crosstalk in chronic inflammation and cancer (lung cancer, inflammation, micro environment)

  • gene function in tumorigenesis (cancer, colorectal cancer, drug targets, targeted drug delivery, diagnosis)

  • biochemical investigations of the heart (heart failure, metabolism, mitochondria, contractile dysfunction)

  • analysis of cancer gene phenotypes (oncogene, tumour suppressor gene, tumour formation)

  • genetic determinants of cancer metastasis (cancer, metastasis)

  • bispecific antibodies for use in cancer therapies (cancer, immunotherapy, bispecific antibodies)

  • diagnosis and therapy of gastrointestinal cancer (cancer, abdomen, optical imaging)

  • action of and intervention in control pathways in cancer (kinase, cancer, drugs)

  • investigation of RAS oncogene mutant cancers (lung cancer, therapy, early detection)

  • investigating cellular protein production (cancer, protein production, gene expression)

  • the phosphoinositide-network in health and disease (inflammation, cancer)

  • understanding the molecular basis for invasion and metastasis of melanoma and pancreatic cancer (cancer metastasis, pancreatic cancer, melanoma)

  • PTEN and the PI 3-kinase signalling pathway (cancer, signalling, pten, tumour suppressor)

  • cancer biology including host immunity in zebrafish (cancer, immunity, zebrafish)

  • the tumour micro environment in cancer progression (cell death, inflammation, lymphoma)

  • mechanisms of normal and leukaemic haematopiesis (haematopoietic stem cells; leukaemia; haematopoiesis)

  • understanding the repair of damaged DNA (DNA damage; repair; cancer; chemotherapy)

  • mechanisms of cancer development (cancer, heterogeneity, stem cells, epigenetic)

  • development and refinement of small animal imaging (imaging, development, biomarkers)

  • novel therapies for malignant germ cell tumours (MicroRNA, germ cell tumour)

  • molecular imaging of cancer (imaging, cancer, instrumentation, contrast)

  • genetics and treatment of acute lymphoblastic leukaemia (acute lymphoblastic leukaemia, measles virus)

  • progressive multifocal leukoencephalopathy (PML) and its network in tissue development and disease (cancer, stem cells)

  • models of lymphomas to identify therapeutic targets (lymphoma, micro environment, targeted therapy)

  • targeted molecular and immune therapies for cancer (cancer, melanoma, immune response, inflammation, immunotherapy)
  • regeneration and cancer in epithelial tissues (stem-cells; regeneration; tumour; epithelial tissues)
Published 25 April 2016